LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
Head and Neck Neoplasms
DRUG: methotrexate|DRUG: afatinib
progression free survival (PFS), defined as the time from the date of randomization to the date of progression evaluated according to RECIST 1.1 or to the date of death, whichever occurs first, up to 2 years
Overall survival (OS), defined as the time from the date of randomization to the date of death (regardless of the cause of death), up to 3 years|Objective response defined as complete response (CR) or partial response (PR) determined by RECIST 1.1 according to the best response to study medication, up to 2 years|Health related quality of life (HRQOL) will be assessed based on patient-reported questionaires, up to 2 years
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.